{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:59:48Z","timestamp":1793923188183,"version":"4.8.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100024172","name":"Schleswig-Holstein","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100024172","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jidinnovations.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JID Innovations"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.xjidi.2026.100450","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T16:15:33Z","timestamp":1768320933000},"page":"100450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Association of immune checkpoint inhibitor-induced bullous pemphigoid with underlying cancer type: A lack of association with cancer tissue COL17A1 mutations and dysregulation"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4963-6926","authenticated-orcid":false,"given":"Rachel C.","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0863-7148","authenticated-orcid":false,"given":"Henning","family":"Olbrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulu F.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley","family":"Gainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Curkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7653-3650","authenticated-orcid":false,"given":"Theresa L.","family":"Walunas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2264-8372","authenticated-orcid":false,"given":"Jessica","family":"Shiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parul","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0857-0556","authenticated-orcid":false,"given":"Adrian P.","family":"Mansini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1394-1737","authenticated-orcid":false,"given":"Ralf J.","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2906-2454","authenticated-orcid":false,"given":"Kyle T.","family":"Amber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xjidi.2026.100450_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2024.102639","article-title":"Changes in the overall survival of patients with metastatic renal cell carcinoma in the era of immune-checkpoint inhibitors","volume":"92","author":"Adhikari","year":"2024","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.xjidi.2026.100450_bib2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/tan.12960","article-title":"A multi-hit hypothesis of bullous pemphigoid and associated neurological disease: is HLA-DQB1\u221703:01, a potential link between immune privileged antigen exposure and epitope spreading?","volume":"89","author":"Amber","year":"2017","journal-title":"HLA"},{"key":"10.1016\/j.xjidi.2026.100450_bib3","doi-asserted-by":"crossref","first-page":"5676","DOI":"10.3390\/cancers14225676","article-title":"Activated eosinophils predict longer progression-free survival under immune checkpoint inhibition in melanoma","volume":"14","author":"Ammann","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xjidi.2026.100450_bib4","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1001\/jamadermatol.2022.1624","article-title":"Association of bullous pemphigoid with immune checkpoint inhibitor therapy in patients with cancer: a systematic review","volume":"158","author":"Asdourian","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.xjidi.2026.100450_bib5","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3163\/1536-5050.104.3.014","article-title":"De-duplication of database search results for systematic reviews in EndNote","volume":"104","author":"Bramer","year":"2016","journal-title":"J Med Libr Assoc"},{"key":"10.1016\/j.xjidi.2026.100450_bib6","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.2147\/CCID.S487711","article-title":"Successful treatment of immune checkpoint inhibitor-induced bullous pemphigoid with omalizumab: a case report and review of the literature","volume":"17","author":"Chen","year":"2024","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.xjidi.2026.100450_bib7","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xjidi.2026.100450_bib8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3390\/antib11030044","article-title":"Deciphering the contribution of BP230 autoantibodies in bullous pemphigoid","volume":"11","author":"Cole","year":"2022","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.xjidi.2026.100450_bib9","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3390\/cancers16020340","article-title":"Incidence of cutaneous immune-related adverse events and outcomes in immune checkpoint inhibitor-containing regimens: a systematic review and meta-analysis","volume":"16","author":"Curkovic","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xjidi.2026.100450_bib10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/ijd.17563","article-title":"Enriched class II HLA inherence in patients with checkpoint inhibitor-associated bullous pemphigoid","volume":"64","author":"Gandarillas","year":"2025","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.xjidi.2026.100450_bib11","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","article-title":"Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US","volume":"7","author":"Ganti","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.xjidi.2026.100450_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"10.1016\/j.xjidi.2026.100450_bib13","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1038\/s41467-020-17965-0","article-title":"A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response","volume":"11","author":"Hakimi","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.xjidi.2026.100450_bib14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2018.11.009","article-title":"Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors","volume":"107","author":"Hasan Ali","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.xjidi.2026.100450_bib15","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jaad.2019.08.045","article-title":"BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors","volume":"82","author":"Hasan Ali","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2026.100450_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - a systematic review and meta-analysis","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.xjidi.2026.100450_bib17","doi-asserted-by":"crossref","first-page":"368","DOI":"10.23736\/S0031-0808.20.03997-X","article-title":"Eosinophils in bullous pemphigoid","volume":"63","author":"Jones","year":"2021","journal-title":"Panminerva Med"},{"key":"10.1016\/j.xjidi.2026.100450_bib18","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3389\/fonc.2020.00352","article-title":"The role of collagen XVII in cancer: squamous cell carcinoma and beyond","volume":"10","author":"Jones","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.xjidi.2026.100450_bib19","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/bjd.21836","article-title":"Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study","volume":"187","author":"Kawsar","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2026.100450_bib20","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/bjd\/ljae219","article-title":"Risk of death, major adverse cardiac events and relapse in patients with bullous pemphigoid treated with systemic or topical corticosteroids","volume":"191","author":"Kridin","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2026.100450_bib21","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/DER.0000000000000792","article-title":"The association of bullous pemphigoid with atopic dermatitis and allergic rhinitis-A population-based study","volume":"33","author":"Kridin","year":"2022","journal-title":"Dermatitis"},{"key":"10.1016\/j.xjidi.2026.100450_bib22","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/(SICI)1097-0142(19960815)78:4<758::AID-CNCR11>3.0.CO;2-U","article-title":"Malignant melanoma: relationship of the human leukocyte antigen class II gene DQB1\u22170301 to disease recurrence in American Joint Committee on Cancer Stage I or II","volume":"78","author":"Lee","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.xjidi.2026.100450_bib23","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3892\/ol.2024.14603","article-title":"Pembrolizumab therapy in a patient with NSCLC and bullous pemphigoid: a case report","volume":"28","author":"Li","year":"2024","journal-title":"Oncol Lett"},{"key":"10.1016\/j.xjidi.2026.100450_bib24","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","article-title":"TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells","volume":"77","author":"Li","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.xjidi.2026.100450_bib25","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.27211","article-title":"Analysis of cancer survival associated with immune checkpoint inhibitors after statistical adjustment: a systematic review and meta-analyses","volume":"5","author":"Lin","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.xjidi.2026.100450_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1516126","article-title":"A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX","volume":"16","author":"Ludwig","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.xjidi.2026.100450_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.823618","article-title":"Immunotherapy in lung cancer: current landscape and future directions","volume":"13","author":"Mamdani","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.xjidi.2026.100450_bib28","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.3390\/biom10101432","article-title":"Bullous pemphigoid: trigger and predisposing factors","volume":"10","author":"Moro","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.xjidi.2026.100450_bib29","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000542958","article-title":"Real-world survival outcomes in patients with different types of cancer managed with immune checkpoint inhibitors","volume":"48","author":"Nieder","year":"2025","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.xjidi.2026.100450_bib30","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.1201","article-title":"Treatment and attrition trends for metastatic clear cell renal cell carcinoma in the US","volume":"8","author":"Ozay","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.xjidi.2026.100450_bib31","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.xjidi.2026.100450_bib32","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/exd.14228","article-title":"The role of dipeptidyl peptidase-4 in cutaneous disease","volume":"30","author":"Patel","year":"2021","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.xjidi.2026.100450_bib33","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.it.2019.04.002","article-title":"Adverse events following cancer immunotherapy: obstacles and opportunities","volume":"40","author":"Pauken","year":"2019","journal-title":"Trends Immunol"},{"key":"10.1016\/j.xjidi.2026.100450_bib34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jaad.2025.03.006","article-title":"Improved survival at the population level for patients with advanced Merkel cell carcinoma following availability of immunotherapy","volume":"93","author":"Paulson","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2026.100450_bib35","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xjidi.2026.100450_bib36","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/ddg.15638","article-title":"Research in practice: immune checkpoint inhibitor related autoimmune bullous dermatosis","volume":"23","author":"Pruessmann","year":"2025","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.xjidi.2026.100450_bib37","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2020.07.027","article-title":"Immune checkpoint inhibitor-induced bullous pemphigoid: towards a new class of drug-drug interaction?","volume":"138","author":"Pujalte-Martin","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.xjidi.2026.100450_bib38","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jama.2024.12848","article-title":"Renal cell carcinoma: a review","volume":"332","author":"Rose","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.xjidi.2026.100450_bib39","article-title":"Retrospective analysis of checkpoint inhibitor therapy-associated cases of bullous pemphigoid from six German dermatology centers","volume":"11","author":"Sadik","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.xjidi.2026.100450_bib40","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/jamadermatol.2022.0354","article-title":"Risk factors for the development of bullous pemphigoid in US patients receiving immune checkpoint inhibitors","volume":"158","author":"Said","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.xjidi.2026.100450_bib41","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.xjidi.2026.100450_bib42","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors : skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.xjidi.2026.100450_bib43","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1727116","article-title":"Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors","volume":"9","author":"Simon","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.xjidi.2026.100450_bib44","doi-asserted-by":"crossref","first-page":"D1210","DOI":"10.1093\/nar\/gkad986","article-title":"COSMIC: a curated database of somatic variants and clinical data for cancer","volume":"52","author":"Sondka","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.xjidi.2026.100450_bib45","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1634\/theoncologist.2015-0498","article-title":"FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1","volume":"21","author":"Sul","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.xjidi.2026.100450_bib46","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1111\/cas.15488","article-title":"Impact of germline HLA genotypes on clinical outcomes in patients with urothelial cancer treated with pembrolizumab","volume":"113","author":"Takahashi","year":"2022","journal-title":"Cancer Sci"},{"key":"10.1016\/j.xjidi.2026.100450_bib47","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/1346-8138.17517","article-title":"Immune checkpoint inhibitor-associated bullous pemphigoid: a retrospective and real-world study based on the United States Food and Drug Administration adverse event reporting system","volume":"52","author":"Tan","year":"2025","journal-title":"J Dermatol"},{"key":"10.1016\/j.xjidi.2026.100450_bib48","doi-asserted-by":"crossref","first-page":"D1334","DOI":"10.1093\/nar\/gkab970","article-title":"OncoDB: an interactive online database for analysis of gene expression and viral infection in cancer","volume":"50","author":"Tang","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.xjidi.2026.100450_bib49","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jamadermatol.2021.5476","article-title":"Association of cutaneous immune-related adverse events with increased survival in patients treated with anti-programmed cell death 1 and anti-programmed cell death ligand 1 therapy","volume":"158","author":"Tang","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.xjidi.2026.100450_bib50","doi-asserted-by":"crossref","first-page":"W98","DOI":"10.1093\/nar\/gkx247","article-title":"GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses","volume":"45","author":"Tang","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.xjidi.2026.100450_bib51","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jamaoncol.2018.5860","article-title":"Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer","volume":"5","author":"Toi","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.xjidi.2026.100450_bib52","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/1346-8138.16654","article-title":"What's new in the pathogeneses and triggering factors of bullous pemphigoid","volume":"50","author":"Ujiie","year":"2023","journal-title":"J Dermatol"},{"key":"10.1016\/j.xjidi.2026.100450_bib53","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/archderm.134.9.1075","article-title":"Evaluation of clinical criteria for diagnosis of bullous pemphigoid. French Bullous Study Group","volume":"134","author":"Vaillant","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.xjidi.2026.100450_bib54","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.trecan.2023.04.002","article-title":"Immune mechanisms of toxicity from checkpoint inhibitors","volume":"9","author":"Wang","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.xjidi.2026.100450_bib55","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaad.2022.12.048","article-title":"Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study","volume":"88","author":"Zhang","year":"2023","journal-title":"J Am Acad Dermatol"}],"container-title":["JID Innovations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026726000019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026726000019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T06:59:03Z","timestamp":1773989943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667026726000019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2667026726000019"],"URL":"https:\/\/doi.org\/10.1016\/j.xjidi.2026.100450","relation":{},"ISSN":["2667-0267"],"issn-type":[{"value":"2667-0267","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of immune checkpoint inhibitor-induced bullous pemphigoid with underlying cancer type: A lack of association with cancer tissue COL17A1 mutations and dysregulation","name":"articletitle","label":"Article Title"},{"value":"JID Innovations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xjidi.2026.100450","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}],"article-number":"100450"}}